NO20081112L - Vevsbeskyttende peptider og anvendelse derav - Google Patents

Vevsbeskyttende peptider og anvendelse derav

Info

Publication number: NO20081112L
Authority: NO; Norway
Prior art keywords: tissue; peptides; protecting; receptor; protective
Prior art date: 2005-08-05

Application number

NO20081112A

Other languages

English (en)

Norwegian (no)

Inventor

Michael Brines

Thomas Coleman

Anthony Cerami

Original Assignee

Araim Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-08-05

Filing date

2008-03-03

Publication date

2008-05-05

2008-03-03 Application filed by Araim Pharmaceuticals Inc filed Critical Araim Pharmaceuticals Inc

2008-05-05 Publication of NO20081112L publication Critical patent/NO20081112L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Immunology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)

NO20081112A 2005-08-05 2008-03-03 Vevsbeskyttende peptider og anvendelse derav NO20081112L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US70574105P	2005-08-05	2005-08-05
US70627605P	2005-08-08	2005-08-08
US83173706P	2006-07-18	2006-07-18
PCT/US2006/031061 WO2007019545A2 (fr)	2005-08-05	2006-08-07	Peptides protecteurs de tissus et leurs utilisations

Publications (1)

Publication Number	Publication Date
NO20081112L true NO20081112L (no)	2008-05-05

Family

ID=37728020

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20081112A NO20081112L (no)	2005-08-05	2008-03-03	Vevsbeskyttende peptider og anvendelse derav

Country Status (25)

Country	Link
US (7)	US8071554B2 (fr)
EP (5)	EP2371855B1 (fr)
JP (6)	JP5274253B2 (fr)
KR (7)	KR20200072568A (fr)
CN (2)	CN103724418B (fr)
AU (1)	AU2006278264B2 (fr)
BR (1)	BRPI0614529A8 (fr)
CA (3)	CA2982909A1 (fr)
DK (3)	DK2540309T3 (fr)
EA (1)	EA015672B1 (fr)
ES (3)	ES2550055T3 (fr)
HU (3)	HUE035655T2 (fr)
IL (3)	IL189287A (fr)
IN (1)	IN2014CN02050A (fr)
LT (2)	LT2540309T (fr)
MX (3)	MX2008001509A (fr)
NO (1)	NO20081112L (fr)
NZ (1)	NZ565937A (fr)
PL (3)	PL2371855T3 (fr)
PT (3)	PT2594279T (fr)
SG (2)	SG2014007868A (fr)
SI (3)	SI2540309T1 (fr)
UA (1)	UA100222C2 (fr)
WO (1)	WO2007019545A2 (fr)
ZA (1)	ZA201101890B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030072737A1 (en) *	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
WO2007052154A2 (fr)	2005-04-29	2007-05-10	University Of Medicine And Dentistry Of New Jersey	Peptide court derive d'erythropoietine et ses mimetiques utilises comme modulateurs immuno / inflammatoires
US9345745B2 (en) *	2005-04-29	2016-05-24	Bo Wang	Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en) *	2005-04-29	2017-03-07	Peter C. Dowling	Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
EP2371855B1 (fr)	2005-08-05	2015-07-22	Araim Pharmaceuticals, Inc.	Peptides protecteurs de tissus et utilisations associées
AR061269A1 (es) *	2006-06-07	2008-08-13	Chugai Pharmaceutical Co Ltd	Composicion y metodo de revascularizacion para el tratamiento de enfermedades isquemicas usando eritropoyetina
DK2081956T3 (da)	2006-11-13	2013-06-24	Charite Universitaetsmedizin	FREMGANGSMÅDE TIL CELLEDYRKNING OG FREMGANGSMÅDE TIL BEHANDLING OMFATTENDE EN vEPO-PROTEINVARIANT
AU2014203195B2 (en) *	2008-01-22	2016-03-31	Araim Pharmaceuticals, Inc.	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2016203452B2 (en) *	2008-01-22	2018-02-22	Araim Pharmaceuticals, Inc.	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2009094172A2 (fr)	2008-01-22	2009-07-30	Araim Pharmaceuticals, Inc.	Peptides protecteurs de tissu et analogues peptidiques pour la prévention et le traitement de maladies et de troubles associés à un endommagement tissulaire
US8791234B2 (en) *	2010-10-14	2014-07-29	Rutgers, The State University Of New Jersey	Intestinal peptide targeting ligands
US9566349B2 (en) *	2010-10-14	2017-02-14	Rutgers, The State University Of New Jersey	Intestinal peptide targeting ligands
CN102180948A (zh) *	2011-03-03	2011-09-14	复旦大学附属中山医院	一种具有肾脏保护作用的短肽及其制备方法和应用
CN102212111B (zh) *	2011-05-05	2014-04-30	中国人民解放军第三军医大学	小分子多肽和小分子多肽脂质体及其运用
WO2013016634A1 (fr) *	2011-07-27	2013-01-31	Neumedicines, Inc.	Utilisation d'il-12 pour générer de l'érythropoïétine endogène
US20140249573A1 (en) *	2011-09-20	2014-09-04	A.A. Cash Technology Ltd.	Methods and devices for occluding blood flow to an organ
KR101148191B1 (ko) *	2011-09-27	2012-05-23	김후정	에리스로포이에틴-유래 펩타이드 및 그 용도
WO2013158871A1 (fr)	2012-04-20	2013-10-24	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Utilisation de l'érythropoïétine et de dérivés pour le traitement de l'hypertension
SG11201600294QA (en) *	2013-07-17	2016-02-26	Araim Pharmaceuticals Inc	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN104744593A (zh) *	2013-12-25	2015-07-01	深圳先进技术研究院	一种抗肿瘤血管生成免疫复合肽及其制备方法和应用
US9622483B2 (en)	2014-02-19	2017-04-18	Corning Incorporated	Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en)	2014-02-19	2021-06-22	Corning Incorporated	Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en)	2014-02-19	2021-06-22	Corning Incorporated	Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
KR20150130616A (ko) *	2014-05-13	2015-11-24	(주)케어젠	피부상태 개선 활성을 갖는 펩타이드 및 이의 용도
CN105924505A (zh) *	2014-06-22	2016-09-07	马恒标	组织保护活性多肽sl12及其应用
CA3001065A1 (fr)	2015-10-14	2017-04-20	Xiaoxi WEI	Compositions et procedes permettant de reduire la formation de cristaux de glace
US10864253B2 (en)	2016-04-29	2020-12-15	Araim Pharmaceuticals, Inc.	Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage
KR102499651B1 (ko) *	2016-11-10	2023-02-13	에이에스씨 리제니티 리미티드	에리트로포이에틴-유래 분자를 함유하는 국소 적용을 위한 미용 제형
WO2018155997A1 (fr) *	2017-02-27	2018-08-30	재단법인 대구경북과학기술원	Utilisation de peptide dérivé d'érythropoïétine au moyen de son effet sur la prévention de la lésion cellulaire
WO2018157773A1 (fr)	2017-02-28	2018-09-07	暨南大学	Peptide de réparation destiné à être utilisé pour favoriser la réparation et la régénération tissulaires post-traumatiques, et son application
CN108503690B (zh) *	2017-02-28	2020-07-03	暨南大学	一种促进创伤后组织修复与再生的修复肽及其应用
WO2019199661A1 (fr) *	2018-04-08	2019-10-17	Brim Biotechnology, Inc.	Application de peptides courts dérivés du pedf dans la cicatrisation des tendons
KR102300060B1 (ko)	2018-06-12	2021-09-08	주식회사 엘지에너지솔루션	2열 터미널 구조의 pcb 다이렉트 커넥터
SG11202102416SA (en)	2018-09-10	2021-04-29	Cold Spring Harbor Laboratory	Methods for treating pancreatitis
CN112390877B (zh) *	2019-08-16	2022-10-04	董红燕	Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用
CN118255845B (zh) *	2022-12-27	2025-07-11	上海瑞吉康生物医药有限公司	相分离逆转多肽的变体及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO812612L (no)	1980-08-06	1982-02-08	Ferring Pharma Ltd	Enzym-inhibitorer.
US4558006A (en) *	1983-02-04	1985-12-10	Kirin-Amgen, Inc.	A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US5051448A (en)	1984-07-24	1991-09-24	The Mclean Hospital Corporation	GABA esters and GABA analog esters
US4704355A (en)	1985-03-27	1987-11-03	New Horizons Diagnostics Corporation	Assay utilizing ATP encapsulated within liposome particles
US4798824A (en)	1985-10-03	1989-01-17	Wisconsin Alumni Research Foundation	Perfusate for the preservation of organs
US5498694A (en)	1989-05-25	1996-03-12	La Jolla Cancer Research Foundation	Peptides of the cytoplasmic domain of integrin
DE3924746A1 (de)	1989-07-26	1991-01-31	Behringwerke Ag	Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
AU6501390A (en)	1989-09-21	1991-04-18	Synergen, Inc.	Method for transporting compositions across the blood brain barrier
US5192746A (en)	1990-07-09	1993-03-09	Tanabe Seiyaku Co., Ltd.	Cyclic cell adhesion modulation compounds
WO2004031211A2 (fr) *	2002-10-03	2004-04-15	Epimmune Inc.	Peptides de liaison hla et utilisations de ces derniers
US6063625A (en) *	1993-02-12	2000-05-16	Board Of Trustees Of Leland S, Stanford, Jr. University	Regulated transcription of targeted genes and other biological events
US5559103A (en)	1993-07-21	1996-09-24	Cytel Corporation	Bivalent sialyl X saccharides
US5571787A (en)	1993-07-30	1996-11-05	Myelos Corporation	Prosaposin as a neurotrophic factor
US5700909A (en)	1993-07-30	1997-12-23	The Regents Of The University Of California	Prosaposin and cytokine-derived peptides
WO1995021919A2 (fr) *	1994-02-14	1995-08-17	Kirin Brewery Company, Limited	Proteine a activite de thrombopoietine (tpo)
ITFI940106A1 (it) *	1994-05-27	1995-11-27	Menarini Ricerche Sud Spa	Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US5576423A (en)	1994-12-02	1996-11-19	Schering Corporation	Antibodies to the slam protein expressed on activated T cells
BR9609006A (pt) *	1995-06-07	1999-12-14	Ortho Pharma Corp	Peptìdeo, composição farmacêutica, e, processo para tratamento dse paciente.
JP2001524944A (ja) *	1997-03-05	2001-12-04	ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア	神経障害性疼痛の緩和方法
US7270809B2 (en) *	1997-07-14	2007-09-18	Bolder Biotechnology, Inc.	Cysteine variants of alpha interferon-2
US7153943B2 (en) *	1997-07-14	2006-12-26	Bolder Biotechnology, Inc.	Derivatives of growth hormone and related proteins, and methods of use thereof
NZ560696A (en)	1999-04-13	2010-03-26	Kenneth S Warren Inst Inc	Use of erythropoietin based medicaments for the protection of a mammal from pathology resulting from injury to excitable tissue
AU2001252650A1 (en) *	2000-04-28	2001-11-12	Effector Cell Institute	Novel derivative of cell chemotactic factor
AU3323002A (en) *	2000-12-20	2002-07-01	Hoffmann La Roche	Erythropoietin conjugates
PA8536201A1 (es) *	2000-12-29	2002-08-29	Kenneth S Warren Inst Inc	Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US20030072737A1 (en)	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US20040063917A1 (en)	2001-02-06	2004-04-01	Carr Francis J.	Modified erythropoietin (epo) with reduced immunogenicity
AU2002319142B2 (en) *	2001-04-04	2008-02-21	Genodyssee	New polynucleotides and polypeptides of the erythropoietin gene
KR100467751B1 (ko) *	2001-12-03	2005-01-24	씨제이 주식회사	생체내 에리스로포이에틴 활성이 증진된 융합단백질
US7300915B2 (en) *	2002-06-05	2007-11-27	The Regents Of The University Of California	Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
JP2006507228A (ja)	2002-07-01	2006-03-02	ザケネスエス．ウォーレンインスティテュート，インコーポレーテッド	応答性の細胞、組織および器官を保護、回復ならびに増強するための組換え型組織保護サイトカインおよびそれをコードする核酸
KR100478455B1 (ko)	2002-08-19	2005-03-22	삼성전자주식회사	전자렌지
JP2006511468A (ja)	2002-09-09	2006-04-06	ウォーレンファーマシューティカルズ，インコーポレーテッド	内因性エリスロポエチンの組織保護活性を維持する長期作用性エリスロポエチン
WO2005025606A1 (fr)	2003-09-09	2005-03-24	Warren Pharmaceuticals, Inc.	Erythropoietines a action prolongee pouvant maintenir une activite de protection tissulaire d'une erythropoietine endogene
JP2004305006A (ja) *	2003-04-01	2004-11-04	Japan Science & Technology Agency	人工調製肺サーファクタント
US7718363B2 (en)	2003-04-25	2010-05-18	The Kenneth S. Warren Institute, Inc.	Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
CN1812800B (zh) *	2003-04-25	2013-01-16	匹兹堡大学	用于促进和增强神经修复和再生的肌肉来源的细胞(mdc)
US7645733B2 (en)	2003-09-29	2010-01-12	The Kenneth S. Warren Institute, Inc.	Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US20080227696A1 (en) *	2005-02-22	2008-09-18	Biosurface Engineering Technologies, Inc.	Single branch heparin-binding growth factor analogs
WO2007010552A2 (fr)	2005-03-17	2007-01-25	Serum Institute Of India Limited	Conjugue d'erythropoietine peg n-terminal
WO2007052154A2 (fr)	2005-04-29	2007-05-10	University Of Medicine And Dentistry Of New Jersey	Peptide court derive d'erythropoietine et ses mimetiques utilises comme modulateurs immuno / inflammatoires
US9345745B2 (en)	2005-04-29	2016-05-24	Bo Wang	Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US8329652B2 (en)	2005-05-10	2012-12-11	Neoloch Aps	Neuritogenic peptides
EP1736481A1 (fr)	2005-05-13	2006-12-27	Charite Universitätsmedizin-Berlin	Variants d'érythropoietine
EP1888098A2 (fr)	2005-05-25	2008-02-20	Neose Technologies, Inc.	Formulations d'erythropoietine glycopegylees
EP2371855B1 (fr)	2005-08-05	2015-07-22	Araim Pharmaceuticals, Inc.	Peptides protecteurs de tissus et utilisations associées
CA2802984C (fr)	2007-11-29	2016-04-12	Molecular Health Gmbh	Nouveau recepteur d'erythropoietine protecteur de tissu (nepor) et procedes d'utilisation
WO2009094172A2 (fr)	2008-01-22	2009-07-30	Araim Pharmaceuticals, Inc.	Peptides protecteurs de tissu et analogues peptidiques pour la prévention et le traitement de maladies et de troubles associés à un endommagement tissulaire
AU2009243187C1 (en) *	2008-04-28	2015-12-24	President And Fellows Of Harvard College	Supercharged proteins for cell penetration
WO2011022056A2 (fr)	2009-08-18	2011-02-24	Medical College Of Georgia Research Institute, Inc.	Modulateurs peptidiques de l'interaction de δpkc avec la sous-unité d de l'atp synthase/atpase f1fo et leurs utilisations

2006
- 2006-08-07 EP EP11163194.1A patent/EP2371855B1/fr active Active
- 2006-08-07 SG SG2014007868A patent/SG2014007868A/en unknown
- 2006-08-07 MX MX2008001509A patent/MX2008001509A/es active IP Right Grant
- 2006-08-07 IN IN2050CHN2014 patent/IN2014CN02050A/en unknown
- 2006-08-07 EP EP12175366.9A patent/EP2594279B1/fr active Active
- 2006-08-07 CA CA2982909A patent/CA2982909A1/fr not_active Abandoned
- 2006-08-07 KR KR1020207016998A patent/KR20200072568A/ko not_active Ceased
- 2006-08-07 US US11/997,898 patent/US8071554B2/en not_active Expired - Fee Related
- 2006-08-07 EP EP12175352.9A patent/EP2540309B1/fr active Active
- 2006-08-07 PT PT121753669T patent/PT2594279T/pt unknown
- 2006-08-07 KR KR1020137016015A patent/KR101713368B1/ko not_active Expired - Fee Related
- 2006-08-07 PL PL11163194T patent/PL2371855T3/pl unknown
- 2006-08-07 ES ES11163194.1T patent/ES2550055T3/es active Active
- 2006-08-07 DK DK12175352.9T patent/DK2540309T3/en active
- 2006-08-07 CA CA3079319A patent/CA3079319A1/fr not_active Abandoned
- 2006-08-07 AU AU2006278264A patent/AU2006278264B2/en not_active Ceased
- 2006-08-07 PT PT111631941T patent/PT2371855E/pt unknown
- 2006-08-07 PT PT121753529T patent/PT2540309T/pt unknown
- 2006-08-07 SG SG10201805825SA patent/SG10201805825SA/en unknown
- 2006-08-07 EA EA200800536A patent/EA015672B1/ru not_active IP Right Cessation
- 2006-08-07 EP EP06801051A patent/EP1924276A4/fr not_active Withdrawn
- 2006-08-07 PL PL12175366T patent/PL2594279T3/pl unknown
- 2006-08-07 ES ES12175366.9T patent/ES2653790T3/es active Active
- 2006-08-07 KR KR1020197019568A patent/KR20190084136A/ko not_active Ceased
- 2006-08-07 CA CA2618396A patent/CA2618396C/fr not_active Expired - Fee Related
- 2006-08-07 ES ES12175352.9T patent/ES2653864T3/es active Active
- 2006-08-07 BR BRPI0614529A patent/BRPI0614529A8/pt not_active Application Discontinuation
- 2006-08-07 CN CN201310529242.5A patent/CN103724418B/zh not_active Expired - Fee Related
- 2006-08-07 LT LTEP12175352.9T patent/LT2540309T/lt unknown
- 2006-08-07 EP EP17202352.5A patent/EP3363451A1/fr not_active Withdrawn
- 2006-08-07 HU HUE12175366A patent/HUE035655T2/en unknown
- 2006-08-07 DK DK12175366.9T patent/DK2594279T3/en active
- 2006-08-07 UA UAA200802850A patent/UA100222C2/uk unknown
- 2006-08-07 KR KR1020087005373A patent/KR101626153B1/ko not_active Expired - Fee Related
- 2006-08-07 SI SI200632233T patent/SI2540309T1/en unknown
- 2006-08-07 WO PCT/US2006/031061 patent/WO2007019545A2/fr not_active Ceased
- 2006-08-07 PL PL12175352T patent/PL2540309T3/pl unknown
- 2006-08-07 HU HUE12175352A patent/HUE035793T2/en unknown
- 2006-08-07 SI SI200632230T patent/SI2594279T1/en unknown
- 2006-08-07 NZ NZ565937A patent/NZ565937A/en not_active IP Right Cessation
- 2006-08-07 DK DK11163194.1T patent/DK2371855T3/en active
- 2006-08-07 JP JP2008525285A patent/JP5274253B2/ja not_active Expired - Fee Related
- 2006-08-07 LT LTEP12175366.9T patent/LT2594279T/lt unknown
- 2006-08-07 KR KR1020187016750A patent/KR20180067735A/ko not_active Ceased
- 2006-08-07 HU HUE11163194A patent/HUE026444T2/en unknown
- 2006-08-07 SI SI200631979T patent/SI2371855T1/sl unknown
- 2006-08-07 KR KR1020177005579A patent/KR20170027868A/ko not_active Ceased
- 2006-08-07 MX MX2016004825A patent/MX364100B/es unknown
- 2006-08-07 MX MX2014011168A patent/MX339613B/es unknown
- 2006-08-07 KR KR1020187030050A patent/KR20180116475A/ko not_active Ceased
- 2006-08-07 CN CN2006800348244A patent/CN101378772B/zh not_active Expired - Fee Related
2008
- 2008-02-05 IL IL189287A patent/IL189287A/en active IP Right Grant
- 2008-03-03 NO NO20081112A patent/NO20081112L/no not_active Application Discontinuation
2011
- 2011-03-11 ZA ZA2011/01890A patent/ZA201101890B/en unknown
- 2011-10-20 US US13/278,131 patent/US8716245B2/en not_active Expired - Fee Related
2012
- 2012-04-16 US US13/448,345 patent/US8673861B2/en not_active Expired - Fee Related
2013
- 2013-02-15 JP JP2013027479A patent/JP5918155B2/ja not_active Expired - Fee Related
2014
- 2014-04-08 US US14/248,030 patent/US9340598B2/en not_active Expired - Fee Related
2015
- 2015-02-04 JP JP2015020020A patent/JP6158235B2/ja not_active Expired - Fee Related
- 2015-02-10 US US14/618,873 patent/US20150152156A1/en not_active Abandoned
- 2015-06-29 IL IL239695A patent/IL239695A0/en active IP Right Grant
2016
- 2016-05-05 US US15/147,848 patent/US10100096B2/en not_active Expired - Fee Related
- 2016-06-08 JP JP2016114010A patent/JP6491621B2/ja not_active Expired - Fee Related
2018
- 2018-04-03 JP JP2018071318A patent/JP2018134084A/ja active Pending
- 2018-08-23 IL IL261346A patent/IL261346A/en unknown
- 2018-09-25 US US16/141,724 patent/US20190016769A1/en not_active Abandoned
2020
- 2020-01-30 JP JP2020013151A patent/JP2020078317A/ja active Pending

Also Published As

Publication number	Publication date
PT2540309T (pt)	2017-12-29
EP2594279A1 (fr)	2013-05-22
SG2014007868A (en)	2014-05-29
HUE026444T2 (en)	2016-05-30
IL261346A (en)	2018-10-31
JP2020078317A (ja)	2020-05-28
US20190016769A1 (en)	2019-01-17
HK1127751A1 (en)	2009-10-09
PL2371855T3 (pl)	2015-12-31
JP2018134084A (ja)	2018-08-30
LT2540309T (lt)	2018-01-10
KR20180116475A (ko)	2018-10-24
US8673861B2 (en)	2014-03-18
ES2653790T3 (es)	2018-02-08
DK2371855T3 (en)	2015-09-21
KR101626153B1 (ko)	2016-06-01
AU2006278264B2 (en)	2012-12-06
KR20200072568A (ko)	2020-06-22
EA200800536A1 (ru)	2009-02-27
DK2540309T3 (en)	2018-01-08
KR101713368B1 (ko)	2017-03-07
EP2371855B1 (fr)	2015-07-22
JP5918155B2 (ja)	2016-05-18
KR20190084136A (ko)	2019-07-15
IL189287A0 (en)	2008-06-05
KR20170027868A (ko)	2017-03-10
US8071554B2 (en)	2011-12-06
EP3363451A1 (fr)	2018-08-22
CA3079319A1 (fr)	2007-02-15
CN103724418A (zh)	2014-04-16
US20090221482A1 (en)	2009-09-03
ES2550055T3 (es)	2015-11-04
CN101378772B (zh)	2013-12-04
EP1924276A2 (fr)	2008-05-28
IL189287A (en)	2015-07-30
KR20080064800A (ko)	2008-07-09
HUE035793T2 (en)	2018-05-28
JP6491621B2 (ja)	2019-03-27
EP2594279B1 (fr)	2017-11-22
WO2007019545A2 (fr)	2007-02-15
ZA201101890B (en)	2012-12-27
CA2982909A1 (fr)	2007-02-15
US10100096B2 (en)	2018-10-16
MX2008001509A (es)	2008-04-04
US20150152156A1 (en)	2015-06-04
EP2371855A1 (fr)	2011-10-05
US20120142595A1 (en)	2012-06-07
UA100222C2 (uk)	2012-12-10
AU2006278264A1 (en)	2007-02-15
EP2540309A3 (fr)	2013-05-29
CA2618396C (fr)	2018-02-27
JP2009508471A (ja)	2009-03-05
SI2540309T1 (en)	2018-04-30
KR20130080481A (ko)	2013-07-12
CN103724418B (zh)	2018-03-06
JP6158235B2 (ja)	2017-07-05
US9340598B2 (en)	2016-05-17
IN2014CN02050A (fr)	2015-05-29
JP2013126995A (ja)	2013-06-27
US8716245B2 (en)	2014-05-06
SI2594279T1 (en)	2018-04-30
CN101378772A (zh)	2009-03-04
JP2016196480A (ja)	2016-11-24
PL2594279T3 (pl)	2018-03-30
SI2371855T1 (sl)	2015-11-30
NZ565937A (en)	2011-09-30
EP2540309B1 (fr)	2017-11-22
HUE035655T2 (en)	2018-05-28
CA2618396A1 (fr)	2007-02-15
PL2540309T3 (pl)	2018-03-30
US20160244498A1 (en)	2016-08-25
LT2594279T (lt)	2018-01-10
EP2540309A2 (fr)	2013-01-02
JP5274253B2 (ja)	2013-08-28
EA015672B1 (ru)	2011-10-31
ES2653864T3 (es)	2018-02-09
EP1924276A4 (fr)	2009-07-22
US20120264682A1 (en)	2012-10-18
PT2371855E (pt)	2015-11-03
US20140323401A1 (en)	2014-10-30
IL239695A0 (en)	2015-08-31
JP2015134772A (ja)	2015-07-27
WO2007019545A3 (fr)	2008-10-02
SG10201805825SA (en)	2018-08-30
PT2594279T (pt)	2017-12-29
KR20180067735A (ko)	2018-06-20
BRPI0614529A8 (pt)	2016-07-12
BRPI0614529A2 (pt)	2011-08-09
MX339613B (es)	2016-06-02
DK2594279T3 (en)	2018-01-08
MX364100B (es)	2019-04-12

Publication	Publication Date	Title
NO20081112L (no)	2008-05-05	Vevsbeskyttende peptider og anvendelse derav
IN2012DN02981A (fr)	2015-07-31
PT1548032E (pt)	2009-08-13	Péptidos kdr e vacinas que os contêm
WO2011036442A3 (fr)	2011-06-30	Polypeptides et leurs utilisations
WO2006090810A3 (fr)	2007-03-29	Vaccins a base de peptides pour cancers du poumon exprimant des polypeptides ttk, urlc10 ou koc1
MX2021011726A (es)	2021-10-22	Escindasas modificadas, usos de las mismas y kits relacionados.
WO2010135491A3 (fr)	2011-04-07	Mutants du facteur de croissance des fibroblastes ayant une meilleure demi-vie fonctionnelle et méthodes d'utilisation associées
EP2030984A4 (fr)	2009-08-26	Peptide antigène anti-cancéreux dérivé de sparc et composition pharmaceutique le contenant
JP2019525753A5 (fr)	2020-07-09
EP2589658A4 (fr)	2013-12-18	Polypeptide de région partielle de la protéine reic/dkk-3
DE602005020165D1 (de)	2010-05-06	Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
WO2005087811A3 (fr)	2006-03-30	Recepteurs des oestrogenes et procedes d'utilisation associes
WO2006131749A3 (fr)	2007-05-18	Echafaudage
DE60336353D1 (de)	2011-04-21	Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
WO2007013358A3 (fr)	2007-07-05	Polypeptides vivit, agent therapeutique les contenant et methode de recherche par criblage d'agent anticancer
WO2007029262A3 (fr)	2009-04-30	Compositions et methodes d'utilisation de ces dernieres en vue de detecter des virus
DK2289533T3 (da)	2013-12-02	Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
WO2005004894A3 (fr)	2005-03-31	Procedes d'augmentation de la viabilite de cellules et de tissus
FI20050753A0 (fi)	2005-07-14	Uudet peptidit
AU2003302901A8 (en)	2004-06-30	Human recombinant endooligopeptidase a (heopa)
ATE538806T1 (de)	2012-01-15	Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
WO2009136033A3 (fr)	2010-04-29	Utilisation cosmetique de proteines de type annexine ii pour le traitement de la secheresse cutanee
EP4047009A3 (fr)	2022-11-16	Peptides à épitope wdrpuh et vaccins les contenant
WO2007020405A3 (fr)	2007-05-03	Nouveaux peptides et utilisations associees
SE9801530D0 (sv)	1998-04-30	Method for screening

Legal Events

Date	Code	Title	Description
2021-08-09	FC2A	Withdrawal, rejection or dismissal of laid open patent application